| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2011: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Research Abstract |
We developed recombinant oncolytic herpes simplex viruses that possess certain antitumor functions and are useful for gastric cancer therapy. A third-generation oncolytic herpes simplex virus type 1(T-01) was used as the backbone to insert foreign sequences. Oncolytic herpes simplex viruses expressing suppressor of cytokine signaling 3 (T-SOCS-3) were constructed, evaluated, and proved to be therapeutic potential. T-SOCS-3 may be a new agent against gastric cancer in the near future, and a progress has been made in the basic development of next generation onoclytic virotherapy.
|
